Amends the law to develop best practices and technical standards for managing AI-related risks in engineering biology. Establishes a consortium to create guidelines for nucleic acid synthesis screening. Allocates $5 million annually for 2025-2029 for these activities.
Analysis summaries, actor details, and coverage mappings were LLM-classified and may contain errors.
This is a binding legislative act from the United States Congress that amends existing law with mandatory obligations, specific funding authorization, and designated enforcement authority through the Director of NIST.
The document has minimal coverage of AI risk domains, with only brief mentions in 2-3 subdomains. The primary focus is on biosecurity and nucleic acid synthesis screening, with AI mentioned only as one risk factor among many in engineering biology. Coverage is limited to malicious actors (4.2) and governance (6.5), with implicit reference to system safety (7.2).
The document primarily governs the Scientific Research and Development Services sector, specifically focusing on biosecurity measures for nucleic acid synthesis. It also has implications for the Health Care sector through biotechnology applications and the Manufacturing sector through biomanufacturing activities.
United States Congress
This is a Congressional Act, as indicated by the legislative format and structure. The document amends existing law (Section 10221 of the Research and Development, Competition, and Innovation Act) through Congressional action.
National Institute of Standards and Technology (NIST); The Director (of NIST); Federal agencies
The Director of NIST is given authority to carry out measurement research, convene the consortium, and develop technical standards and best practices. NIST receives specific appropriations to execute these activities, and the Director consults with other Federal agency heads.
National Institute of Standards and Technology (NIST); The Director (of NIST); Committee on Commerce, Science, and Transportation of the Senate; Committee on Science, Space, and Technology of the House of Representatives
The Director is responsible for monitoring through the consortium's activities and must submit a report to Congressional committees. The Congressional committees receive reports summarizing findings, establishing oversight. The consortium itself evaluates impact and effectiveness of implementation.
industry; institutions of higher education; nonprofit organizations; customers; nucleic acid synthesis providers
The Act targets entities involved in nucleic acid synthesis and engineering biology, including those using AI in these contexts. The consortium explicitly includes industry, higher education institutions, nonprofits, and customers as stakeholders who must follow the screening mechanisms and best practices.
3 subdomains (3 Minimal)